This pattern gives a first target to return to level A at about 8.10-8.20 and a second target to return to level C at around 8.50.
Anticipated Catalysts for remaining 2022:
NA/US Licensing Vyleesi ROW Licensing Vyleesi PL3994 PH2 Heart Failure Data Diabetic Nephropathy PH 2 Initiate Study
Something should also happen with the preferred shares at the end of September. (Convertible at $11.25 to common shares, Redeemed for debt, or basically cancelled)
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.